Company intelligence / Profile preview

HD Immune

Ownership: Private
Development stage: Preclinical

Overview

HD Immune has demonstrated in preclinical studies that its lead monoclonal antibody, C6‑17, lowers levels of mutant huntingtin protein in blood, organs, and CNS. In transgenic mouse models of Huntington’s disease, this led to improved motor performance. The company is currently humanizing the antibody for future clinical trials.

Therapeutic areas: Neurology
Modalities: monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

C6-17

Pre-clinical

Indications: Huntington's disease

Partnerships

Institute of Molecular Biotechnology at BOKU/University of Natural Resources and Life Sciences Vienna (academic collaboration for research programs)Austrian Centre of Industrial Biotechnology/acib Comet24 program support

Beyond the preview

Go deeper on HD Immune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HD Immune.

Explore the full profile